Site icon pharmaceutical daily

Osteoarthritis Pain Pipeline Review, H2 2020: Therapeutics Development & Assessment, Drug Profiles, Dormant Projects, Discontinued Products, Product Development Milestones – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Osteoarthritis Pain – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Osteoarthritis Pain – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 7, 22, 8, 1, 12, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

Reasons to Buy

Key Topics Covered:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/4kmlrv

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version